Manejo Del Dolor Con Medicamentos Guna (Ampollas y Gotas)

COMPLEMENTOS CON MEDICAMENTOS
EUROLIFE
FELIPE TORRES MD.

M.R.F. , Terapia Celular
EL DOLOR
COMPLEMENTOS R.P.M
MEDICAMENTOS
INTRODUCCIÓN
El dolor es una sensación subjetiva, polimorfa y

multidimensional. Difícil de cuantificar.
INTRODUCCIÓN
SENSACIÓN SUBJETIVA:
Mezcla la percepción y la
estructura psicológica del
sujeto.
INTRODUCCIÓN
FISIOLOGÍA DEL DOLOR
La nocicepción comprende dos

etapas:
1- La transducción del estímulo nocivo

por las terminaciones nerviosas
periféricas
2- La transmisión de esas señales hacia el

sistema nervioso central.
El impulso nociceptivo se modula en cada

nivel de la vía sensitiva aferente, desde
el nervio periférico hasta la corteza
cerebral.
INTRODUCCIÓN
DIFERENTES TIPOS DE DOLOR:
-AGUDO: Se acompaña de reacciones

somatoegetativas y de ansiedad.
-CRONICO (más de 6 meses): Se

acompaña de tendencias depresivas,
irritabilidad, trastornos del sueño,
del apetito y de la líbido.
- EXPERIMENTAL
- CLINICO
CARACTERÍSTICAS DEL DOLOR
Los dolores son clasificados, de acuerdo con su origen, en:
SOMÁTICOS
VISCERALES
NEURÓGENO
SOMÁTICOS
Cuando la sensación dolorosa se produce a nivel de la piel,

del aparato locomotor o del tejido conectivo, se habla de
dolor somático.
Puede adoptar 2 formas:
• Dolor superficial: cuando el estímulo se localiza a nivel
de la piel
• Dolor profundo: el que se produce a nivel muscular, óseo
o del tejido conjuntivo
SOMÁTICOS
El dolor superficial, que se produce por ejemplo luego de

un pinchazo, se compone de 2 partes:
- El primer dolor superficial tiene un carácter agudo, es

bien localizado y desaparece rápidamente luego de
frenado el estímulo. Este estímulo doloroso suele
acompañarse de reacciones rápidas de huida, como el
retirar el pie al pisar un pedazo de vidrio, a fin de evitar
más daños al organismo.
SOMÁTICOS
- A este dolor superficial primario le sigue a menudo un

dolor superficial secundario, que en general es de carácter
sordo o urente, que es más difícil de localizar y que
desaparece más lentamente. Este dolor superficial
secundario es neurológicamente idéntico al dolor profundo,
que origina, por ejemplo la cefalea - una de las formas de
dolor más común que afecta a los seres humanos.
VISCERALES
El contrapuesto al dolor somático es el dolor visceral.

Es semejante a un dolor de carácter sordo y, junto con las
reacciones de tipo vegetativo, al dolor profundo. Aparece
por frente a la dilatación o los espasmos (en el dolor
menstrual) de la musculatura lisa, en las hemorragias y en
los procesos inflamatorios.
Se puede presentar como dolor duradero como en los
dolores estomacales o de tipo periódico como en los
cólicos.
Ej. de dolor lumbar visceral: el provocado por una úlcera
duodenal o por una endometriosis.
NEURÓGENO
Junto al dolor somático y al visceral se puede presentar
finalmente el dolor neurógeno.
Se origina por el estímulo de fibras nerviosas, cuando las

mismas son dañadas o interrumpidas, presentando un
carácter agudo.
Ejemplos de este tipo de dolor es la neuralgia del trigémino y

el dolor fantasma luego de amputaciones: el individuo
afectado refiere dolor del miembro amputado. El estímulo
doloroso se origina a nivel del muñón de la amputación.
Además de su origen el dolor puede diferenciarse de acuerdo

con su duración:
AGUDO
CRÓNICO
AGUDO
El dolor agudo tiene un tiempo limitado, desapareciendo

rápidamente. Este dolor puede tolerarse incluso sin
medicamentos como en los tratamientos odontológicos.
CRÓNICO
El dolor crónico puede presentarse como duradero en el

dolor lumbar o tumoral o recurrente como en las cefaleas o
angina de pecho). Los dolores crónicos son en general
difíciles de tolerar.
No todos los dolores tienen su origen en los receptores

dolorosos:
PSICÓGENO
PSICÓGENO
A veces puede prevalecer una afección psicológica, en la
cual el paciente no puede manifestar sus conflictos de otra
manera que refiriendo dolores.
La afección psicológica puede presentarse bajo una forma

somática, como un dolor.
INTRODUCCIÓN
MECANISMOS PERIFERICOS:
SENSIBILIDAD PUNTUAL DE LA PIEL
El exámen de la sensibilidad de la piel a estímulos muy
localizados permite observar que la sensibilidad varía de un
punto a otro; muy baja en algunos puntos y muy elevada en
otros.
También se ha podido establece la existencia de puntos

cutáneos que responden al tacto, al frío, al calor y a al dolor.
Para cada tipo de sensación se han dibujado mapas para cada

región diferente del cuerpo. Estos mapas sufren fluctuaciones
con el tiempo y con el estado de la piel.
INTRODUCCIÓN
INTERVENCIONES TERAPÉUTICAS:
NIVEL PERIFÉRICO
Encadenamiento neuronal responsable de la

transmisión de la información a los centros
NOCICEPTORES
Existen una categoría de receptores que no pueden ser

estimulados más que por estímulos intensos de origen
diversos. Estas estimulaciones pueden ser realizadas en tres
condiciones:
1- Lesión tisular originada por punción, presión, rotura o

quemadura.
2- Inflamación tisular consecuente de las anteriores o

directamente provocada por agentes químicos exógenos o
endógenos.
3- Isquemia secundaria a la reducción del débito sanguíneo

NOCICEPTORES
A pesar de la diversidad de los estímulos, es posible hablar de

nociceptores delante de los criterios siguientes (definidos por
Iggo):
Umbral a estímulos elevado: esto se aplica, sobre todo, a

nociceptores mecánicos o térmicos cuyo umbral elevado
contrasta con el umbral bajo de los mecano o de los
termoreceptores específicos.
Pequeña superficie del campo receptor.
Descarga de tipo tónico, poco adaptable, persistente después

de la parada del estímulo.
Inervación por fibras de pequeño diámetro (A delta y C).

AREA INFLAMADA
SUSTANCIAS ALGOGENAS
KININAS: Son un grupo de sustancias que también actúan

como mediadores de la inflamación:
- BRADIKININA: Se libera en las quemaduras

cutáneas. La inyección local en el hombre provoca
dolor por a descarga de las fibras C.
- PROSTAGANDINAS: La PGEl y PGE2, intervienen de

manera evidente en la inflamación. Las perfusiones
subcutáneas de PGE1 a muy bajas concentraciones en
el hombre producen hiperalgesia. Este efecto es
antagonizado por la aspirina, la indometacina, los
corticoides y por la PG F2 alfa.
MAGNETOTERAPIA
IMANES TERAPEUTICOS
INTERVENCIONES TERAPÉUTICAS
NIVEL PERIFERICO: Con nutrientes:
-Nutrientes que inhiben las citoquinas, prostaglandinas

y leucotrienos.
-Nutrientes que intervienen en la reparación de los tejidos

dañados por la inflamación.
-Nutrientes de apoyo antioxidante.

INTERVENCIONES TERAPÉUTICAS
NIVEL PERIFERICO: Con Complejos Homeopáticos:
Siguiendo la reacción de Bystander
Inmunologia
La inflamación periférica es regulada por el S.N.C.
La afinidad del TCR, por los complejos peptídicos

asociados al MHC, aumenta en la medida en que los
contactos sean mas repetitivos.
Inmunologia
El MALT secreta
El TNF-alfa y la IL-1
TGF beta-1, que
es estimulados por
induce la
lipopolisacaridos
producción le
bacterianos y en
linfocito B e IgA.
menor estímulos
antigenos virales.
El interferon(IFN) se gama o beta se producen

básicamente por el estimulo de antigenos virales.
Inmunologia
Se puede sufrir el síndrome de las mucosas

parcial o totalmente, según el numero de
mucosas comprometidas.
Inmunologia
El MALT, se considera un
El fenómeno
órgano linfoidede entre
Hominglas
de mucosas,
los leucocitos,
en laso que
volver
al sitio de sensibilización
intervienen las mucosas
antigénica,
respiratorias explica la el
y digestivas,
manifestación
TGU comparte drenaje y la
fisiopatologica
presencia del
de tejido linfoide
síndrome
similar de las mucosas
al intestinal.
Inmunologia
Psiconeuroendocrinoinmunologia : interacción entre

los sistemas neuroendocrino e inmune, así como el
estudio de los cambios conductuales que dicha
interacción produce.
La interacción es bidireccional
Inmunologia
Influye la mente en El cerebro y la

la susceptibilidad
de enfermar, o en
respuesta inmune
la facilidad para
recuperarse de una
enfermedad?
Lesiones del hipotálamo,
sistema limbico, o
formación reticular
Lateralización hemisférica
de la respuesta inmune
Sustento inmunológico
Sustento inmunológico
Clonación en
ganglios Son atraídos por
linfáticos. quimiotaxis o por
organotropismo o
histotropismo.
Neuroendocrinoinmunologia
ES EL CAMPO
CIENTÍFICO
INTERDISCIPLINARIO
QUE INVESTIGA LAS
RELACIONES ENTRE EL
CEREBRO ( MENTE-
CONDUCTA) Y EL
SISTEMA INMUNE Y
SUS CONSECUENCIAS
CLINICAS
This material is based on the presenter’s
studies in PHYSIOLOGICAL REGULATING
MEDICINE.
The information presented here is not to be

considered a prescription and we do not
accept medical or legal responsibility for
misuse of the information presented. This
information is for educational purposes for
licensed health care professionals within their
scope of practice.
43
© Dipartimento Scientifico Guna S.p.a.
What You Will Learn Today
1. LOW DOSE S.K.A. - PRINCIPLES OF HOMEOPATHY
1. NEW CHEMICALS WITH S.K.A. TECHONOLOGY
1. CYTOKINES: ITS RELEVANCE IN PAIN AND

INFLAMMATION
1. EXPERIMENTAL DATA TO VALIDATE CYTOKINE

POTENCY IN ANIMAL MODEL
1. CLINICAL APPLICATION OF LOW DOSE S.K.A. IN

PAIN MANAGEMENT AND AESTHETIC MEDICINE
Physiological Regulating Medicine
PRM
WESTERN COMPLEMENTAR
CONVENTION Y ALTERNATIVE
AL MEDICINE MEDICINE
45
PRM DRUGS
A new pharmacological concept: one
biotherapeutic medicine blending synergistic
ingredients from Complementary Alternative
Medicine and Conventional Medicine to achieve a
positive clinical outcome.
Homeopathic Science Molecular Biology
MINERAL, NEUROPEPTIDES,
PLANT, CYTOKINES,
ANIMAL HORMONES,
DERIVATIVES GROWTH FACTORS
PHYSIOLOGICAL REGULATING MEDICINE (PRM)
The science of PRM integrates state of the art scientific advances

in:

•Homeopathy
•Homotoxicology
•Psycho Neuro Endocrine Immunology (PNEI)
•Nutritional and Phyto-Medicine
To formulate biotherapeutic medicines achieving the best
individualized prescription for patients to promote recovery
from illness and restoration of health Quantu
m
Molecula Physics
Homeopat
r Biology hy
P.N.E. Nutrition
I. al Homotoxicolo
Medicine gy
Homeostatic control systems
P CENTRAL NERVOUS SYSTEM
N
&
NEUROVEGETATIVE
SYSTEMS
E ENDOCRINE
SYSTEM
I IMMUNE SYSTEM
Ader, R., Psychoneuroimmunology, IV edition, vol. 1 e 2, Academic Press, Amsterdam

2007. © Dipartimento Scientifico Guna S.p.a.
Da: PsicoNeuroEndocrinoImmunologia. Francesco Bottaccioli – RED Edizioni
 The hormones influence cytokines levels
and realize a connection between endocrine
system and immune system
◦ FEMALE SEXUAL HORMONES inhibit the Th2
reaction and stimulate Th1 cytokines
◦ CORTISOL inhibit the Th1 reaction and in

particular IL-2. In turn, different interleukins,
among which IL-1, IL-6, TNF-α, IFN stimulate
ACTH secretion and therefore also cortisol
secretion
◦ IL-1, TNF-α, IFN-γ and in
particular IL-6 have a
fundamental role in the thyroid
function: they inhibit the iodide
uptake organification, they hinder
thyreocytes growth,
thyreoglobulin synthesis and the
release of thyroid hormones,
hepatic deionization which in turn
activates T4 to T3
◦ IL-1 β and TNF-α inhibit TRH,
stimulating the secretion of
somatostatine
◦ IL-6 has an indirect inhibitory
effect through the cortico adrenal
stimulation
P.N.E.I. NETWORK AND
PSYCHE MESSENGER MOLECULES
NEUROPEPTIDES
P
N
HORMONES
HORMONES
E
I INTERLEUKINS
SOMA PSYCHE
I E N P

Messenger Molecules
The Foundation for PRM
COMMUNICATING MOLECULES are

messengers, the words used by the 3
homeostatic control systems to speak
each other …and to understand each
other.
53
P.N.E.I. NETWORK AND
MESSENGER MOLECULES
EVERY DISEASE IS THE EXPRESSION,

THE CONSEQUENCE OF CHANGED
CONCENTRATION OF MESSENGER
MOLECULES
54
PSYCHE
THE P.N.E.I. NETWORK
NEUROPEPTIDES
MOSCHUS
P NUX VOMICA
N
HORMONES
INTERLEUKINS
I
SOMA PSYCHE
I E N P

PSYCHE
THE P.N.E.I. NETWORK
P NEUROPEPTIDES
N
HORMONES
HORMONES
E
I INTERLEUKINS
SOMA PSYCHE
I E N P

DISEASE
HYPER-CONCENTRATION
10-
6
HEALTH
4C – X6
PHYSIOLOGICAL CONCENTRATION
10-15
HYPO-CONCENTRATION
DISEASE © Dipartimento Scientifico Guna S.p.a.

DEFINITIONS
g (gram)= 1
10 -1 = 0.1
10 -2 = 0.01
mg (milligram)= 10 -3 = 0.001
μg (microgram)= 10 -6 = 0.000001
ng (nanogram)= 10 -9 = 0.000000001
pcg (picogram)= 10 -12 = 0.000000000001
fg (fentogram)= 10 -15 = 0.000000000000001

PRM
PRM codifies the vision of the
physiologic milieu of the organism as a
psycho-neuro-endocrine-immune
NETWORK regulated by mechanisms
of FINE CONTROL (sensitive ligand-
receptor control mechanisms)
59
Physiological Regulating Medicine:
…a dynamic new concept
PRM moves from classical Homeopathy
to the revolutionary therapeutic
concept of restoring physiology
through administration of
communicating molecules-hormones,
interleukins, neuropeptides and growth
factors-prepared in homeopathic
dilutions, which are equivalent to the
physiologic concentrations found in the
human body (biological milieu).
60
PRM
The homeopathic preparation method
of “dilution-dynamization” makes these
communicating molecules even more
effective.
61
EFFECTS OF DIFFERENT DOSES OF CYTOKINES
TM
TOXIC
TOXIC CONCENTRATION EFFECT
10- mg/ml
3
PHARMACOLOGICAL SIDE EFFECTS
EFFECTS PHARMACOLOGICAL CONCENTRATION
10- mcg/ml
6
MINIMAL EFFECTIVE PHARMACOLOGICAL DOSE
WITH WITHOUT
DYNAMIZATION: PHYSIOLOGICAL CONCENTRATION DYNAMIZATION:
PHYSIOLOGICAL NO BIOLOGICAL
ng-pcg/ml
EFFECTS Or PHYSIOLOGICAL
EFFECTS
10-15
MINIMAL EFFECTIVE PHYSIOLOGICAL DOSE
62
DYNAMIZATION=S.K.A.
S. Sequential
K. Kinetic
A. Activation
• Hypothalamus • Thyroid
– Somatostatine – TSH
– Beta-Endorphin – Triiodohyronine
(T3)
• Hypophysis – Thyroxine (T4)
– FSH – Calcitonin
– LH
– ACTH • Parathyroids
– Prolactin – Parathormone (PTH)
– TSH
• Ovary
• Pineal Gland – Beta-Estradiol
– Melatonin – Progesterone

Neuropeptides of PRM
• HyIpothalamus e Hypophysis
– Beta-Endorfin
• Nucleus of rafe of Bulbo, of Bridge and of

Mesencefalo. Stomach and bowel
– Serotonin
• Pineal Gland
– Melatonin

© Dipartimento Scientifico Guna S.p.a. in cooperation with:
Effects of different doses of IL-1-β on

isolated human fibroblasts
66
66
68
Expression of NFKb and c-
fos on isolated fibroblasts
nfkb
lps a c d b lps a c d
1h 18h
c-fos
lps a c d b lps a c d
1h 18h

Expression of NFKb and c-fos
on isolated fibroblasts
Legend
•lps=control
•A=placebo (water and alcohol)
•B=pharmacological concentration
•C=4CH diluted and dynamized
•D=4CH only diluted but not
dynamized
THE IMMUNE SYSTEM
Th1 Th2
71
71
Th-1/Th-2 BALANCE
Th-2 Th-1
IL-4 IL-12
IL-5 Th-1 Th-2 IFN-
IL-12 IL-4
IFN- IL-5
Crohn’s Asthma
Psoriasis Atopy
72
…in Allergy
Th1
Th2

STIMULATES Th0
STIMULATES
IL-12 IL-4
Th1 Th2
INF-γ, IL-12 IL-4

INHIBITS
INHIBITS
INF-γ
THE CONCEPT OF BALANCE

Developing Th subsets results in cross-regulation. While IL-4
stimulates Th2 differentiation and inhibits diffentiation of Th1 cells,
IL-12 and IFN-γ stimulates Th1 differentiation and inhibits the
development of Th2 cells.
Cooke , A. Th17 in Inflammatory Conditions. 2006, Rev Diabetic Stud 3: 72-7
- Bettelli E. et al. Th17: The third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:
652-657
The interleukins are able to
rebalance the Immune System in
Allergy
IL-12 Th1
IFN-
Th2 ASTHMA
IL-4
IL-5

75
Healing from Asthma
Th1 Th2
IL-12 IL-4
INF- IL-5
76
© Dipartimento Scientifico Guna 76
S.p.a.
© Dipartimento Scientifico Guna S.p.a. in cooperation with:
Effects of low dose cytokines in

treatment of inflammatory
pathologies: use in an animal model
of allergic asthma
77
77
EXPERIMENTAL PROTOCOL
DAY 1 DAY 7 DAY 13
LUCKY Injection of 1 Injection of 1 Aerosol of 1

MOUSE mg of egg- mg of egg- mg of egg-
albumin + 5 albumin + 5 albumin + 5
mg Al(OH)3 in mg Al(OH)3 in mg Al(OH)3 in
PBS (IP) PBS (IP) PBS
TREATMENT WITH IL-12+IFN-γ

from DAY 18 until DAY 38 ALLERGIC
Blood drawing MOUSE
DAY 38 DAY 30 DAY 27

Bronchoalveolar 5% egg-albumin Injection of 1
lavage fluid in PBS 0,5. mg of egg-
(Aerosol) albumin + 5 mg
Al(OH)3 in PBS
Asthma Th1
BALF – after treatment with egg albumin and Al (OH) 3 Th2
180
Legend
60 160 •1-Untr=healthy
mouse
140 •2-OVA=allergic
50 mouse
[IL-5] (pcg/ml)
120
[IL-4] (pcg/ml)
40
100
30 80
60
20
40
10
20
0 0
UNTR OVA UNTR OVA

Protocol Groups to test efficacy of
treatment with 2 anti-allergic
interleukins in combination (IL-
12+IFN-γ) in the allergic mouse
Legend
•1-Untr--healthy mouse
•2-OVA--allergic mouse
•3-OVA+ALLO--IL-12+IFN-γ in
pharmacological concentration
•4-OVA+4CH--IL-12+IFN-γ in
physiological concentration (4CH) dilution
and dynamized
•5-OVA+4CHn--IL-12+IFN-γ in
Level of IL-4 and IL-5 in mice Treatment plan of allergic mouse with the 2 anti-
allergic interleukines in association
sera (IL-12+IFN-γ)
on day 7th of treatment Legenda

70 Levels of IL-4 •1-Untr=healthy mouse
•2-OVA=allergic mouse
•3-OVA+ALLO=IL-12+IFN-γ in pharmacological
60
concentration
•4-OVA+4CH=IL-12+IFN-γ in physiological
concentration (4CH) diluted and dinamized
50
•5-OVA+4CHn=IL-12+IFN-γ in physiological
concentration (4CH) only diluted but not dinamized
40
IL-4 pg/ml
30
20
180 Levels of IL-5
10
160
0 140
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH
1 2 3 4 5 120
100
IL-5 pg/ml
80
60
40
20
0
1 2 3 4 5
Treatment plan of allergic mouse with the 2 anti-
Level of IL-12 and INF-γ in mice allergic interleukines in association
(IL-12+IFN-γ)
sera Legenda
on day 7th of treatment •1-Untr=healthy mouse
2500
Levels of IL-12 •2-OVA=allergic mouse
•3-OVA+ALLO=IL-12+IFN-γ in pharmacological
concentration
•4-OVA+4CH=IL-12+IFN-γ in physiological
2000
concentration (4CH) diluted and dinamized

•5-OVA+4CHn=IL-12+IFN-γ in physiological
concentration (4CH) only diluted but not dinamized
1500
IL-12 pg/ml
1000
Level of IFN-γ
500
6000
0 5000
1 2 3 4 5 4000
IFNgamma pg/ml
3000
2000
1000
0
1 2 3 4 5
Unit of measurement…
…the mistery… that is not a
mistery
we give… …we detect in
the blood
fg pg
4CH

Eosinophil numbers in mouse
BALF (bronchoalveolar lavage
fluid)
on day 20 of treatment
UNTREATED 0
OVA=CONTROL (ALLERGIC MOUSE) 20,188±0,613
OVA+ALLO (PHARMACOLOGICAL TREATMENT) 0
OVA+4 CH (4 CH SKA-ACTIVITED TREATMENT) 0
OVA+4 CH n (4 CH not-SKA-ACTIVITED TREATMENT) 19,567±0,685
OVA+30 CH (30 CH SKA-ACTIVITED TREATMENT) 20,788±0,416
Number of cells expressed in cells/BALF (x 104)

Safety of clinical use of SKA treated

low doses of interleukines
Preliminary datas
IL-12 IFN-g
30,00 50
45
25,00
[IFNgamma] (pg/ml)
40
35
[IL-12] (pg/ml)
20,00
30
15,00 25
20
10,00 15
5,00 10
5
0,00 0
Untr OVA+100ng/die OVA+4CH din Untr OVA+100ng/die OVA+4CH din
PRM
ANTI AGING
THERAPIES
86
Cell
GUNA Cell
Stimulation
Low Tissue
GUNA Matrix
Reactivity Stimulation
Hormonal GUNA
Stimulation Female/Male
Immune
Citomix
Stimulation
ELDERLY
Generic
People
High Level of
Drainage
Intoxication
Specific
GUNA Flam
High Level of Anti
Inflammation Inflammation
IL-10
Ivo BIANCHI M.D. ©
ANTI AGING GENERAL STRATEGY
•CEREBRUM COMP.: 1 ampoul
•GUNA-FEM/MALE: 20 drops evry 2 days for 2-4 months
twice a day for 2-4 months (elderly people)
+
GUNA-FLAM: 20 drops twice a
day for 2-4 months •GUNA-GERIATRICS:
•MELATONIN 4CH: 20 drops at 20 drops twice a day
evening every day for 2-4 months
+ for 2-4 months
•IGF1 4CH: 20 drops at evening every
day for 2-4 months (anti-neoplastic
and anti-oxidant action)
•IL2 4CH: 20 drops twice a day for 2-

•GUNA-MATRIX: 20 drops
4 months (it is the “amti-aging twice a day for 2-4 months
interleukine) +
•GUNA-CELL: 20 drops twice a
•CNTF 4CH: 20 drops twice a day for day for 2-4 months
2-4 months (brain aging)
88
Trophic effect Catabolic effect
Anti aging Anti cancer
GH Somatostatin
DHEA T3
IGF-1 Melatonin
 In animals longlife is correlated with:
◦ High levels of :
 IGF-1
 Melatonin
GUNA-MATRIX •Ac. D-L malicum 6X*
•Natrium oxal. 6X*
•Pyrogenium 12X*
•Fucus 3X* •Natrium pyruv. 6X*
•Tyrosine 2X** •NADID 6X*
•Phenilalanine 2X** •Trychinoil 6X*
•Histidine 2X** •Vit. C 2X*
•Ac. L(+) lacticum3X**
•Deactivation (through •Stimulation of
inflammation) and mitochondrial energy
neutralization of the production.*
impregnated toxins*.
•Matrix acidification
•Synergistic action with (promoting connective tissue
Fucus and thyroid hormone reactivity).**
activating the Action against Matrix
sympatheticotonic nervous liquification •IL 6 4C*
toxin
system**.
impregnation and drainage •DHEA 6X*
•Pyrogenium 12X*
•Hyaluronidase 6X* •Conjunctive Tissue 6X*
Lymphatic
•Thuja 6/8/12/30/200X** •Tyrosine 2X**
drainage •Phenilalanine 2X**
•Natrium sulfuricum 6/8/12/30/200X **
•Prolactine 6X*** •Histidine 2X**
•DHEA 6X*** •Prolactine 6X***
•Increase of Fundamental
•Matrix hydrolysis*
Substance kinetics (protein
•Action against the constitutional hydrolysis, hyper-ionicity,
tendency to impregnation of the histaminic activity, increased
matrix with toxins and to the •Lymphatic vessel 6X temperature) and matrix
development of Dysmetabolic turnover rate.*
Mesenchymopathy
•Inactive toxins mobilized •Sympatheticotonic
(psychcosis).**
towards the lymphatic circle stimulation.**
•Matrix solubilization.*** for drainage 91
© Dipartimento Scientifico Guna S.p.a. •Vagotonic inhibition.***
• Regulation of the
The 3 pillars… in a drug Aconitum*
extracellular matrix Belladonna*
function through the
modulation of the
GUNA-FLAM Ferrum phosphoricum*
Apis*
hypophysary hormons Bryonia*
action and the pineal Pyrogenium*
gland stimulation. Phytolacca*
Natrium pyruvicum*
Acidum citricum*
Cu-gluconate*
Anti IL 1-alfa**
TGF 1 beta***
IL 10***
Melatonin 4C
Hypophysis porcine 200X
Pineal Gland 6X
Conjunctive tissue 12X • Modulation of the
neurogenic, vasal exudative
phases of the inflammatory
process*.
Hepar sulfuris • Hindrance to the
Pyrogenium inflammation start point**.
Aconitum*
Ferrum phosphoricum Beta-endorphin** • Potentiation of the
immunologic anti-
inflammatory activity
having Th2-Th3 polarity***.
• RES stimulation and hindrance

to the possible septic
progression of the • Modulation of the neurogenic phase of
inflammatory process. inflammation*.
• Sensitization of the beta-endorphin peripheral
receptors**.
GUNA CELL -lipoic-ac. 3X
• Carrier action*. Succinic. ac. 3X
• Reprogramming of cell function**. Fumaric. ac. 3X
• 2nd function messenger***. Methyglyoxal 10X
Ac.-L-carnitine* 2X Increase of energetic

DNA** 6X metabolism.
RNA** 6X
Collinsonia 2X***
cAMP 6X***
Mn-gluc. 3X
Mn-phosph. 6X
Mg-phosph. 3X
P 4X
Anti-degenerative and
Ca-gluc. 3X
anti-aging action.
Vitamins Fe fumar. 3X
Colchicum 6/12/30X S 3X
Conium 6/12/30X Se 3X
Podophyllum 6/12/30X Cu sulph. 3X
Methyglyoxal 10X Vit. E Zn-gluc. 3X
Vit. C K-aspart. 3X
Vit. B1, B2, B3, B5,
B6, B9, B12 Catalytic action on
enzyme functions.
Coenzyme activity performing catalytic
action on cell functions. 93
Neurotrophins Hormones
10 pg
NT3 NT4 BDNF IGF-1 Melatonin
Homeopathic
Remedies
Aminoacids Hormones Suis-Organs
Catalysts
D6
D3
Thyrosine TRH ACTH Acidum Baryta Hepar Hypothalamus

DL-malicum carbonica
Phenilalanine Oxitocine Baryum Acidum Arnica Lobo

oxalsuccinicum pyruvicum frontalis
Plumbum Glandula
LH-RH Parabenzochinon
metallicum suprarenalis
Herbals
(Arnica montana)
Catalysts
and
aminoacids
Growth factors
Hormones
Courtesy from Dr. I Bianchi
Insulin
Melatonin ACTH
Growin Factor

Oxitocine TRH LH-RH

• Circulating melatonin decreases with age and
in recent years much interest has been
focused on its immunomodulatory effect.
• Melatonin stimulates the production of
progenitor cells for granulocytes-
macrophages. It also stimulates the
production of NK cells and CD4+ cells and
inhibits CD8+ cells.
• The production and release of various
cytokines from NK cells and T-helper
lymphocytes also are enhanced by melatonin. Melatonin has the potential
• Melatonin presumably regulates immune therapeutic value to enhance
function by acting on the immune-opioid
network, by affecting G protein-cAMP signal immune function in aged
pathway and by regulating intracellular individuals and in patients in
glutathione levels. an immunocompromised
state.
 Insulin-like growth factors (IGFs) are polipeptides with high
sequence similarity to insulin
 IGF-1 is mainly secreted by the liver as a result of
stimulation by GH.
 IGF-1 is important for both the regulation of normal
physiology, as well as a number of pathological states,
including cancer
 IGF axis has been shown to play roles in the promotion of
cell proliferation and inhibition of apoptosis
 Factors that are known to cause variation in the levels IGF-
1 in the circulation include an individuals genetic make-up,
the time of day, age, sex, exercise, stress levels, genetics,
nutrition level and body mass index (BMI), disease state,
race, estrogen status and xenobiotic intake.
 It was demonstrated that administration of ACTH
led to facilitation of learning and strengthening of
memory processes (conditioned reflex traces).
ACTH promoted strengthening of movement,
orientational-investigative, and intersignal
activities, produced hyperalgesia, and blocked the
effects of naloxone
 ACTH is involved in motivation, learning and
memory.
 ACTH restores the ability of hypophysectomised
rats to acquire an avoidance response in a
shuttlebox.
 Oxytocin is a mammalian hormone that also acts as a
neurotransmitter in the brain.
 Oxytocin is released during orgasm in both sexes.
 In the brain, oxytocin is involved in social recognition and
bonding, and might be involved in the formation of trust
between people, in generosity and in the reduction of fear
 Can impair memory retrieval in certain aversive memory
tasks.

 The brain tripeptide thyrotropin-releasing
hormone (TRH) has been demonstrated to
facilitate cholinergic neurotransmission.
 TRH markedly attenuated scopolamine-
induced impairment of some measures of
memory, most notably on a selective
reminding task.
 Cognitive study suggest a facilitatory role
for TRH in human memory processes.
 Scientific studies suggest that stimulation
of TRH may be useful for treatment of age-
related emotional disorders and memory
disturbance in dementia.

 Neurotrophic factors are endogenous
proteins that alter the survival,
development, maintenance, and
differentiation of neurons.
 Evidence has indicated that
neurotrophic factors may be
implicated in the normal functional
activity of nerve cells.
 These molecules are generally small,
soluble proteins with molecular
weights between 13 and 24 kDa and
are often active as homodimers
(1,2).2
 Nerve Growth Factor (NGF) The first
known neurotrophin, acts predominantly
on sympathetic and sensory neurons.
 Brain Derived Neurotrophic Factor (BDNF)
Supports motoneuron development and
survival in animals and prevents naturally
occurring death
 Neurotrophin 3 (NT-3) NT-3 is related to
NGF and has homology with it. It is found
in motorneurons, sympathetic neurons
and some peripheral sensory organs.
 Neurotrophin 4 (NT-4) NT 4 also is related
to NGF and has similar homology. NT-4 is
produced in skeletal Muscle but
production of NT-4 was found to depend
on muscle activity
• Acting on certain CNS neurons and on the peripheral
nervous system
• Helps to support the survival of existing neurons and
encourage the growth and differentiation of new
neurons and synapses
• Active in the Hyppocampus, Cortex, Basal Forebrain
areas vital to learning, memory, and higher thinking.
• Although the vast majority of neurons in the brain are
formed prenatally, parts of the adult brain retain the
ability to grow new neurons from neural stem cells in
a process known as Neurogenesis

 BDNF is one of the most active neurotrophins. Mice
born without the ability to make BDNF suffer
developmental defects in the brain and sensory
nervous system, and usually die soon after birth,
suggesting that BDNF plays an important role in normal
neural development
 BDNF is actually found not only in the brain but also
in a range of tissue and cell types : Retina, Motor
neurons, Kidneys and Prostate.
 Various studies have shown possible links between low
levels of BDNF and conditions such as : Depression,
Schizofrenia, Obsessive Compulsive Disorders,
Alzheimer Disease, Untington’s Chorea, Rett Syndrome,
Dementia, Anorexia and bulimia Nervosa

 Neurotrophin-3 (NT-3) supports the survival
and differentiation of neurones in the central and
peripheral nervous systems through a number of
mechanisms that occur in a matter of hours or
days. NT-3 may also have a more rapid mode of
action that influences synaptic activity in mature
neurones. NT-3, have been implicated in the
regulation of synaptic transmission and plasticity.
 Neurotrophin 4 (NT4) is required for the
synaptic plasticity mediating both tolerance and
memory. NT4 may be involved in neural plasticity
underlying opiate tolerance
 Increasing amounts of evidence indicate that inflammatory processes
are involved in the neurotoxicity of AD. A central event in these
processes appears to be the activation of microglia by a variety of
factors, including b amyloid and proinflammatory cytokines.
 Activated microglia in turn release proinflammatory cytokines, such as
IL-1-b, IL-6, and TNF-, that may lead to neuronal death and
dysfunction by a variety of mechanisms, including
◦ enhancement of glutamate-induced excitotoxicity[
◦ inhibition of long-term potentiation, which limits functional
plasticity after neuronal injury[
◦ inhibition of hippocampal neurogenesis.

IL-6
Upregulated .: IL-10
TNF 
Alzheimer’s Diseases
Downregulated .: IL-2
DEMENTIA
IL-6
Upregulated .: IL-10
IL-1b
Vascular Dementia
Downregulated .: IL-2

Thyroxine Fenilalanilne

 Nonessential amino acid synthesized in the body from phenylalanine. As a building
block for several important brain chemicals, tyrosine is needed to make epinephrine,
norepinephrine, serotonin, and dopamine, all of which work to regulate mood.
 Deficiencies in this amino acid is associated with depression.
 Tyrosine also aids in the production of melanin and in the function of the adrenal,
thyroid, and pituitary glands. Tyrosine is also involved in the synthesis of enkephalins,
substances that have pain-relieving effects in the body.
 Low levels of tyrosine have been associated with low blood pressure, low body
temperature, and an under active thyroid.
 Because tyrosine binds unstable molecules (called free radicals) that can potentially
cause damage to the cells and tissues, it is considered a mild antioxidant. Thus,
tyrosine may be useful for people who have been exposed to harmful chemicals (such
as from smoking) and radiation.
Hepar suis
•Support of Digestive and Detoxicatory Functions
Suprarenal suis
•Opposing Age and Stress Related Endocrine disfunctions
Hypothalamus suis
•Resetting of biological clock
Lobus frontalis suis

•Antagonizing Cognitive deterioration
Application of antagonostic
low dose SKA-activeted
cytokines model in
Autoimmune Diseases and
Muscle-Skeletical Pain
Management

INFLAMMATION
Inflammation ANTI-Inflammation
Cytokines Cytokines
•IL-1 •Anti-IL-1
•TNF-α •IL-4
•IL-6 •IL-10
116
116
INTERLEUKINE-1 (α; ß)
Interleukin 1 (IL-1) cytokine

secreted by macrophages,
monocytes, dendritic cells,
fibroblasts and endothelial
cells
• IL-1 support inflammatory
processes
• Stimulates prostaglandins
production © Dipartimento Scientifico Guna S.p.a.
IL -1
INFLAMMATION SYNOVIAL CARTILAGE BONE

PANNUS BREAKDOWNS RESORPTION
FORMATION

IL-1 (α; ß) ACTION MECHANISM
IL-1 (α; ß) activate:

1.cyclooxygenase type 2
(COX2)
2.prostaglandin E2 (PGE )
2
3.nitric oxide (NO)

CONVENTIONAL DRUGS TO STOP
INTERLEUKINE-1 EFFECTS
NSAIDs CORTISO ASA
- -
N
-
COX2 PGE2 NO

Low dose SKA-actived Antibody Anti
Interleukins -1 (α and β) in Pain
Management
IL-
BLOCK Anti IL-1
1
- Anti Interleukins-1 (α;
ß) act as NSAIDs (A),
COX2 PGE2 NO cortisone (B) and, in
part, as salicylates (C),
without the negative
side effects caused by
these allopathic
medicines.
THERAPEUTIC APPROACH WITH
LOW DOSE S.K.A. ANTIBODY ANTI IL-1, IL-4 &
IL-10 IN MUSCLE-SKELETAL PAIN MANAGEMENT
• Anti IL-1 4CH  Decrease of acute

inflammation.
• IL-10 4CH  Decrease of chronic

inflammation.
• IL-4 4CH  Control of autoimmune

diseases trigger. © Dipartimento Scientifico Guna S.p.a.
• Cytokines are effective
• However pharmacological doses is

plagued with severe adverse effects
Unless…
1. Marinaro, M. et al. 1999. Use of intransal IL-12 to target predominantly
Th1 responses to nasal and Th2 resposnses to oral vaccines given with
cholera toxin. J. Immunol. 162(1): 114-121
2. Mariinaro, M. et al. 1997. Oral but not parenteral interleukin IL-12
redirects T helper 2 (Th2)-type resposnses to an orola vaccine without
altering mucosal IgA responses. J. Exp. Med. 185(3): 415-427
3. Lee, S. Y. et al. 2001. Oral administration of IL-12 suppresses
anaphylatctic reactions in a murine model of peanut hypersensitivity. Clin.
Immunol. 101(2): 220-228
4. Vial,
© Dipartimento T. et
Scientifico Gunaal.
S.p.a. 1995. Immune mediated side-effects of cytokines in
ENDORPHIN
Endorphins are organic chemical substances

produced by the CNS, having antipain and
physiological characteristics similar to those of
morphine and opium – however they have a wider
range
Endorphins, like a number of morphinic origin

alkaloids, can cause states of euphoria and
somnolence according to the quantity released

PRM: What is derived from Homeopathy?
The study of the pharmacological effects of homeopathized
PLANT, MINERALS and ANIMAL COMPONENTS on
healthy humans and their usage depending on the principles
of similarity and effect inversion

in an ill subject.
125
Aconitin experimentation
Pennec, J.P., Aubin, M (1984) – Effect of Aconitum and Veratrum on
the isolated and perfused heart of the common eel. Comp. Biochem,
Physiol. 776:367.
Different effects of Aconitin concentrations on isolated and perfused
eel heart:
• Aconitin 10
X5
-5 M  Fibrillation
• Aconitin 10
X7
-7 M  Bradycardia
• Aconitin 10
X18
-18 M  No effect on
healthy heart
 Rythm
normalization
on preintoxicated
Hauss Experimentation (1968)
STUDIES ON THE "NONSPECIFIC MESENCHYMAL REACTION" AND THE “1 TRANSIT ZONE" IN MYOCARDIAL LESIONS AND
ATHEROSCLEROSIS
W. H. Hauss, U. Gerlach, G. Junge-Hülsing, H. Themann W. Wirth
Annals of the New York Academy of Sciences, Volume 156, Experimental "Metabolic" Cardiopathes and their Relationship
to Hima Heart Disease, Page 207-218, Jan 1969, doi: 10.1111/j.1749-6632.1969.tb16729.x
Effects of varying glucocorticoid concentrations on mesenchymal system turn-over

(connective tissue biological activity)
25000
S-cpm/100g SMPS
20000 Control
5 mg cortisone
15000 0.5 mg cortisone
0.0005 mg cortisone
10000 0.00005 mg cortisone
0.000005 mg cortisone
35
5000
0
Effects of high dose Strycnos Nux vomica on acetylcholine receptors of
gastric mucosa parietal cells
HCl (hydrochloric
+ acid)
proton
pomp Parietal cell of
gastric mucosa
+
Acetylcholine receptor
acetylcholine
+++ High dose

Strycnos
+ Nux
vomica
parasympathetic fiber Increased excitability of

parasympathetic fibers
Effects of homeopathic dose Strycnos Nux vomica on acetylcholine
receptors of gastric mucosa parietal cells
HCl (hydrochloric
- acid)
proton
pomp Parietal cell of
gastric mucosa
-
Acetylcholine receptor
Acetylcholine
Homeopathic
---- dose
Strycnos
Nux vomica
parasympathetic fiber Decreased excitability of

parasympathetic fiber
Important homeopatic single
remedies for Pain Management:
• ARNICA (Arnica montana) • ACIDUM FORMICICUM

• ACONITUM (Aconitum napellus) • GNAPHALIUM POLYCEPHALUM
• RHUS TOX. (Rhus toxicodendron) • RHODODENDRON CHRYSANTHUM
• CIMICIFUGA (Cimicifuga racemosa)• LACHESIS MUTUS
• VIOLA ODORATA • BRYONIA ALBA
• CAULOPHYLLUM (Caulophyllum • HYPERICUM PERFORATUM
talictroides) • BELLADONNA (Atropa belladonna)
• ACIDUM BENZOICUM • CROTALUS HORRIDUS
• LEDUM (Ledum palustre) • KALMIA LATIFOLIA
• COLOCYNTHIS (Citrullus • ETC.
colocynthis)

Homeopathic and Molecolar
• Regulation of ECM Aconitum*
(extracellular matrix) Biology remedies… in 1 drug Belladonna*
function through Ferrum phosphoricum*
modulation of
hypophyseal hormone
GUNA-FLAM Apis*
Bryonia*
action and pineal gland Pyrogenium*
stimulation Phytolacca*
Natrium pyruvicum*
Acidum citricum*
Cu-gluconate*
Anti IL 1-alfa**
TGF 1 beta***
IL 10***
Melatonin 4C
Pineal Gland 6X
Conjunctiva tissue 12X • Modulation of the
neurogenic, vascular
exudative phases of the
inflammatory process*.
Hepar sulfuris • Inhibition of the
Pyrogenium inflammatory cascade starting
Aconitum* point**.
Ferrum phosphoricum Beta-endorphin**
• Potentiation of immunologic
anti-inflammatory activity
• RES(reticuloendothelial
system) stimulation and
inhibition of the possible • Modulation of the neurogenic phase of
septic progression of the inflammation*.
inflammatory process.
receptors**.
SUPPORTIVE ORAL THERAPY IN
PAIN MANAGEMENT
Directions
•GUNA-FLAM: 20 drops twice a day

for at least 1 month

THE CONNECTIVE TISSUE
Morpho-functional unity: vessel-matrix-
membrane receptor
MATRIX
VESSELS

MEMBRANE
RECEPTORS
GUNA-MATRIX •Ac. D-L malicum 6X*
•Natrium oxal. 6X*
•Pyrogenium 12X*
•Fucus 3X* •Natrium pyruv. 6X*
•Tyrosine 2X** •NADID 6X*
•Phenilalanine 2X** •Trychinoil 6X*
•Histidine 2X** •Vit. C 2X*
•Ac. L(+) lacticum3X**
•Deactivation (through
•Stimulation of
inflammation) and mitochondrial energy
neutralization of the production.*
impregnated toxins*.
•Matrix acidification
•Synergistic action with (promoting connective tissue
Fucus and thyroid hormone reactivity).**
activating the Action against Matrix
sympatheticotonic nervous
toxin liquification •IL 6 4C*
system**. •DHEA 6X*
impregnation and drainage
•Pyrogenium 12X*
•Hyaluronidase 6X* •Conjunctive Tissue 6X*
Lymphatic •Tyrosine 2X**
•Thuja 6/8/12/30/200X**
drainage •Phenilalanine 2X**
•Natrium sulfuricum 6/8/12/30/200X **
•Prolactine 6X*** •Histidine 2X**
•DHEA 6X*** •Prolactine 6X***
•Increase of Fundamental
•Matrix hydrolysis*
Substance kinetics (protein
•Action against the constitutional hydrolysis, hyper-ionicity,
tendency to impregnation of the histaminic activity, increased
matrix with toxins and to the •Lymphatic vessel 6X temperature) and matrix
development of Dysmetabolic turnover rate.*
Mesenchymopathy
•Inactive toxins mobilized •Sympatheticotonic
(psychcosis).**
towards the lymphatic circle stimulation.**
•Matrix solubilization.*** 134
for drainage
© Dipartimento Scientifico Guna S.p.a. •Vagotonic inhibition.***
GUNA-LYMPHO Myosotis 3X
Equisetum 3X
D-L Malic Ac./Fumaricum Ac./Pyruvicum Ac.
Trychinoil/Natrium oxalac.
Hydrocotile 1X
•Reduction of local Taraxacum 1X
inflammation on lympho- Sarsaparilla 3X
epithelial tissues. Lymphatic vessel 6X
•Stimulation of Lymph
Capillary tisssue 6X
• Reduction of lymphatic flow with stabilization of
L-Thyroxin 6/12X
spasm due to vessel wall tone with
Vein porcine 6X
inflammation with consequent reduction of
restoration of the the exudate and the
lymphatic circulation. REACTIVATION OF THE lymphoedema.
LYMPHATIC
CIRCULATION
HYPERTROPHY Hydrastis 1X
ANTI-INFLAMMATORY
AND HYPERPLASIA Juglans 3X
Calendula 1X ACTIVITY ON THE
OF THE LYMPHATIC Graphites 6/12/30/200X
Phytolacca 3X LYMPHO-EPITHELIAL ORGANS
Apis 8X TISSUES
Magnesia phosph.
6/12/30/200X
STRENGHTENING
IMMUNE DEFENCE
•Inhibition of the
•Stimulation of proliferative tendencies
Humoral Immunity of the lympho-epithelial
and inhibitory tissues
modulation of the Magnesium
excessive cell phosphoricum
mediated 6/12/30/200X
compensatory 135
Juglans regia 3X
response © Dipartimento Scientifico Guna S.p.a.
DRAINAGE THERAPY IN
PAIN MANAGEMENT
Directions
•GUNA-MATRIX: 20 drops twice a day

for at least 2 months
•GUNA-LYMPHO: 20 drops twice a day
ALL THE A.M. PRODUCTS CAN BE TAKEN TOGETHER (for
example putting 30-40 drops of each medicine in 1 litre
bottle of water. The patient drinks this bottle during the
whole day)

PAIN MANAGEMENT
- LOCAL THERAPY -
137
More than 35%
of patients
suffers from
MSK
conditions.
P.R.M. in
Pain
Management
Give relief to patients
in a NATURAL and
BIOLOGICAL WAY and
WITHOUT SIDE
Chart of area/zoneconnections
GUNA-NECK
GUNA- SHOULDER
GUNA - THORACIC
GUNA-HIP
GUNA-LUMBAR
GUNA-ISCHIAL
GUNA-HANDFOOT
GUNA-NEURAL GUNA- POLYARTHRITIS GUNA-MUSCLE

Nervepain Joint pain Musclepain
THERAPEUTIC UNIT
Every ampoule
contains 10 active
ingredients; 7 of
them are specific
for a specific type
of pain or parts of
the body; 3 of them
are specific for pain
mechanisms. © Dipartimento Scientifico Guna S.p.a.
INFLAMMATION
Inflammation ANTI-Inflammation
Interleukine Antibody
•IL-1 •Anti-
IL-1
142
142
INTERLEUKINE-1 (α; ß)
Interleukin 1 (IL-1) cytokine

secreted by macrophages,
monocytes, dendritic cells,
fibroblasts and endothelial
cells.
IL-1 SUPPORTS
INFLAMMATORY PROCESSES

IL-1 (α; ß) ACTION MECHANISM
IL-1 (α; ß) activates:

1.cyclooxygenase type 2
(COX2)
2.prostaglandin E2 (PGE )2
3.prostaglandin D2 (PGD ) 2
4.nitric oxide (NO)

IL -1
INFLAMMATION SYNOVIAL CARTILAGE BONE

PANNUS BREAKDOWNS RESORPTION
FORMATION

CONVENTIONAL DRUGS TO STOP
INTERLEUKINE-1 EFFECTS
NSAIDs CORTISO ASA
- -
N
-
COX2 PGE2/D2 NO

Low dose SKA-activated Antibody Anti
Interleukins -1 (α and β) in Pain
Management
IL-
BLOCK Anti IL-1
1
- Anti Interleukin-1 (α; ß)
acts as NSAIDs ,
COX2 PGE2 NO cortisone and, in part,
as salicylate , without
the negative side effects
caused by these
allopathic medicines.
β-ENDORPHIN
Endorphins are organic chemical substances

produced by the CNS, having antipain and
physiological characteristics similar to those of
morphine and opium – however they have a wider
range.
Endorphins, like a number of alkaloids, such as

morphin, can cause states of euphoria and
sleepness according to the quantity released.

Concentration of Anti IL-1 (α;
β) and β-endorphin
10-
6
HEALTH
4C – X6
PHYSIOLOGICAL CONCENTRATION
10-15

Important homeopatic single
remedies in P.R.M. Pain
Management ampoules:
• ARNICA (Arnica montana) • ACIDUM FORMICICUM
• ACONITUM (Aconitum napellus) • GNAPHALIUM POLYCEPHALUM
• RHUS TOX. (Rhus toxicodendron) • RHODODENDRON CHRYSANTHUM
• CIMICIFUGA (Cimicifuga racemosa)• LACHESIS MUTUS
• VIOLA ODORATA • BRYONIA ALBA
• CAULOPHYLLUM (Caulophyllum • HYPERICUM PERFORATUM
talictroides) • BELLADONNA (Atropa belladonna)
• ACIDUM BENZOICUM • CROTALUS HORRIDUS
• LEDUM (Ledum palustre) • KALMIA LATIFOLIA
• COLOCYNTHIS (Citrullus • ETC.
colocynthis)

PAIN MANAGEMENT
TREATMENT PROTOCOL
•Standard protocol for i.m. administration:
1 ampoule 1-3 times a week according to
severity and clinical evolution.
•Standard protocol according to

mesotherapeutic technique:
1-2 ampoules per treatment: 2 treatments
for the first 2 weeks, then 1 treatment a week
till pain relief (average 8-10 sessions).
For chronic pathologies: continue 1
treatment a week for 1 month till pain relief,
then 1 treatment a month. 152
SUPPORTIVE ORAL THERAPY IN
PAIN MANAGEMENT
Directions
•GUNA-FLAM: 20 drops twice a day

for at least 2
months

Homeopathic and Molecular
• Regulation of ECM Aconitum*
(extracellular matrix) Biology remedies… in 1 single Belladonna*
function through
modulation of drug: GUNA-FLAM Ferrum phosphoricum*
Apis*
hypophyseal hormone Bryonia*
action and pineal gland Pyrogenium*
stimulation Phytolacca*
Natrium pyruvicum*
Acidum citricum*
Cu-gluconate*
Anti IL 1-alfa**
TGF 1 beta***
IL 10***
Melatonin 4C
Pineal Gland 6X
Conjunctiva tissue 12X • Modulation of the
neurogenic, vascular
exudative phases of the
inflammatory process*.
Hepar sulfuris • Inhibition of the
Pyrogenium inflammatory cascade starting
Aconitum* point**.
Ferrum phosphoricum Beta-endorphin**
• Potentiation of immunologic
anti-inflammatory activity
• RES(reticuloendothelial
system) stimulation and
inhibition of the possible • Modulation of the neurogenic phase of
septic progression of the inflammation*.
inflammatory process.
receptors**.
DRAINAGE THERAPY IN
PAIN MANAGEMENT
Directions
•GUNA-MATRIX: 20 drops twice a day
+
•GUNA-LYMPHO: 20 drops twice a day
ALL THE A.M. PRODUCTS CAN BE TAKEN TOGETHER (for
example putting 30-40 drops of each medicine in 1 litre (33
fl oz) bottle of water. The patient drinks this “therapeutic
cocktail” during the whole day).

•WHERE: intradermal
•HOW MANY POINTS: 5-6-7
•HOW MUCH: 0.3-0.5 ml each injection
156
SYRINGES FOR PAIN
MANAGEMENT
2,5 5 ml 10 ml 20 ml INSULIN
ml

NEEDLES FOR PAIN
MANAGEMENT
13
mm.
LENGHT
GAUGE 30 G

Example of P.R.M. Pain Management ampoule:
GUNA®-POLYARTHRITIS
• Reduction of polyarticular pain •Beta-Endorphin 4C
symptomatology in acute
inflammation having different
• Pain symptomatology
localization
reduction by means of UP-
P.N.E.I. REGULATION of b–Endorphin
receptors
antalgic core
Anti-
Acute
•Salycilicum acidum 2X
inflammatory
inflammatory
•Aconitum 6X
core •Anti interleukin 1 alpha 4C
pain
•Drosera 8X
•Colchicum autumnale 10X
•Anti interleukin 1 beta 4C
•Guaiacum 10X Chronic
inflammatory pain
• Modulation of IL1  and

IL1 b pro-inflammatory
• Reduction of degenerative activity in the trigger
•Ledum palustre 8X phase of inflammation
articular pain on a chronic-
evolutive basis •Viscum album 10X
159
GUNA®-NECK
Clinical Indications
Neck pain due to cartilage degenerative cervical
spine disorders (cervical osteoarthrosis)
 Neck pain due to cervical muscular trigger points
 Stiff neck syndrome
 Simple neck pain
 Whiplash
 Postural neck ache
 Mechanical imbalance (facet joint syndrome)
 Cervical spinal ligament syndrome
 Cervical spinal nerve root pain
 Arnold syndrome
160
GUNA®-NECK • Magnesia phosphorica 12X
•Picricum ac. 8X
• Crotalus horridus 10X
• Nux vomica 10X
• Beta-Endorphin 4C
Reduction of cervical rachis
pain symptomatology of
different origin:
•• Pain symptomatology
Riduzione reduction by means
della sintomatologia
of UP-REGULATION of b–Endorphin • Fibromyalgic origin (Picricum
algica per UP-REGULATION dei acidum)
receptors
recettori della b–Endorfina P.N.E.I. Homeopathic
• Spastic and/or congestive
antalgic core antalgic core origin (Crotalus horr., Nux
vomica, Magnesia phosph.)
Anti- Anti-
• Nevralgic origin (Magnesia
• Stimulation of osteoblasts function phosph.)
degenerative inflammatory
and correction of articular structure core 2 core Anaesthetic origin:
pathologies • Picricum acidum
Anti-
degenerative
core 1
• Anti interleukin 1 alpha 4C

• Silicea 4X
• Anti interleukin 1 beta 4C
• Biostimulation cartilage matrix

• Cartilago suis 4X • Modulation of IL1  and IL1 b
components synthesis (Cartilago)
pro-inflammatory activity in the
•Intervertebral disk, Porcine 4X
• Anti-degenerative action (Discus trigger phase of inflammation
intervertebralis)
161
GUNA®-NECK into specific and selected
local Acupuncture Points
GB 21
GV 16
GB 20 SI 10
BL 10
GV 15
GB 21 SI 9
GV 14
162
GUNA®-NECK into Trigger Points and referred pain
zones
TP
BL 10
SI 15
TP/SI 14 TP
C7
C7 BL 11
TP = Main Trigger Points and correlated Acupuncture points
163
GUNA®-THORACIC
Thoracic pain due to cartilage degenerative thoracic
spine disorders (thoracic osteoarthrosis)
 Thoracic pain due to scoliosis
 Thoracic pain due to thoracic long muscle trigger
points
 Pain due to thoracic spine osteophytosis
 Simple posterior thoracic pain (thoracic pain
syndrome)
 Mechanical imbalance (costo-vertebral facet joint
syndrome)
 Thoracic spinal ligament syndrome
 Thoracic spinal nerve root pain
 Pain from spinal osteoporosis
164
•Chelidonium majus 4X
GUNA®-THORACIC •Cimicifuga racemosa 4X

•Conium maculatum 6X
•Chininum sulphuricum 8X
• Beta-Endorphin 4C •Spongia tosta 10X
Reduction of the dorsal rachis

pain symptomatology of
different origin, type and
•• Pain symptomatology
Riduzione reduction by means
della sintomatologia localization:
of UP-REGULATION
algica of
per UP-REGULATION b–Endorphin
dei
receptors Neuro-muscular
recettori della b–Endorfina P.N.E.I. Homeopathic origin(Cimicifuga, Chininum
antalgic core antalgic core sulph., Conium)
•Spastic and/or congestive
origin(Chelidonium, Spongia)
Anti-
•Constitutional correction of Constitutional core LOCALIZATION
inflammatory
articular structure pathologies core Dorsal rachis: direct, all; hepatic
reflex, Chelidonium.
Anti-
degenerative Intercostal pain: Spongia
core

• Calcarea phosphorica 6X
•Intervertebral disk, Porcine 4X

activity in the trigger phase
•Anti-degenerative and anti-
of inflammation
neuralgic action 165
GUNA®-LUMBAR
 Lumbar pain due to cartilage degenerative lumbar
spine disorders (lumbar and lumbar-sacral arthrosis)
 Lumbar vertebral osteophytosis
 Low back pain due to muscular and tendinous
trigger points
 Simple lumbar pain (low back syndrome)
 Weak low back syndrome
 Postural low back ache
 Lumbar and lumbar-sacral mechanical imbalance
 Lumbar and lumbar-sacral spinal ligament
syndrome
 Sacro-iliac syndrome
 Spinal lumbar and lumbar-sacral nerve root pain
166
Reduction of the lumbar rachis
pain symptomatology of different
origin, type and localization:
GUNA®-LUMBAR
•Neuro-muscular origin (Bryonia,
Alumina, Ac. Phosphoricum).
Articular origin (Natrium sulph.) •Beta-Endorphin 4C
•Type – cramp-like pain (Ac.

phosphoricum); muscular paresis •Pain symptomatology
phenomena (Alumina) reduction by means of UP-
REGULATION of
P.N.E.I. b–Endorphin receptors
•Localization – Lumbosacral
rachis: direct, Hamamelis; Antalgic core
abdominal reflex, Sepia
Anti-
Homeopathic inflammatory
antalgic core core •Anti interleukin 1 alpha 4C

Anti-degenerative
•Bryonia 4X core
•Sepia officinalis 4X
•Phosphoricum ac. 6X
•Modulation of IL1  and
•Hamamelis virginiana 6X
•Alumina 8X
activity in the trigger
•Natrum sulphuricum 8X
phase of inflammation
Intervertebral disk, Porcine 4X
•Anti-degenerative and anti-
neuralgic action 167
GUNA®-ISCHIAL
Sciatica pain
Lumbar-sciatic pain
Nerve pain in the lower
lumbar spine
Leg nerve pain due to
post-surgery treatment of
disk herniation L4-L5, L5-S1
Morton neuroma
168
GUNA®-ISCHIAL • Anti interleukin 1 alpha 4C
• Anti interleunin 1 beta 4C

• Modulation of IL1  and IL1 b

• Pain symptomatology reduction by pro-inflammatory activity in the
means of UP-REGULATION of b– trigger phase of inflammation
Endorphin receptors Anti-inflammatory
P.N.E.I. core
antalgic core
• Modulation of abdominal wall

Reflexed Primary neuralgic
reflexed sciatic pain (Lachesis) and neuralgic pain pain •Lachesis mutus 8X
iliac-sacral lumbar pain (Cimicifuga) •Gnaphalium polycephalum 4X
Secondary •Arsenicum album 6X

neuralgic pain •Rhododendron chrysantum 6X
•Aconitum napellus 8X
• Cimicifuga 4X
• Lachesis mutus 8X Modulation of sciatic pain by
means of inflammation
•Cimicifuga 4X neurogen phase inhibition
• Pain modulation by means of a (Aconitum and Arsenicum)
reduction in the progression of •Rhus toxicodendron 4X and direct action on the sciatic
osteochondrosis (Cimicifuga), nerve (Gnaphalium)
coxo-femoral arthrosis(Rhus tox.),
backache (Rhus tox).
169
GUNA®-SHOULDER
Scapular-humeral peri-arthritis
Shoulder pain
 Shoulder-arm syndrome
Frozen shoulder
 Shoulder pain due to dislocation, therapeutic rest
 Epicondylitis
170
Reduction of shoulder pain of
different origin and type:
GUNA®-SHOULDER
• Neuralgic origin (Argentum
nitricum, Ferrum phosph., Iris)
•Beta-Endorphin 4C
• Muscular origin (Ranunculus,
Sanguinaria)
• Acute pain (Ferrum, Iris) reduction by means of UP-
• Chronic pain (Argentum REGULATION of b–Endorphin
nitricum, Ranunculus) P.N.E.I. receptors
antalgic core
Homeopathic Anti-
antalgic core inflammatory
core •Anti interleukin 1 alpha 4C
•Argentum nitricum 8X
•Ferrum phosphoricum 8X Anti-
degenerative
•Iris versicolor 8X
core
•Sanguinaria canadensis 8X
• Ranunculus bulbosus 10X
activity in the trigger
•Cartilago suis 4X phase of inflammation
•Tendon, Porcine 6X
• Anti-degenerative and chronic anti-
inflammatory action (Tendon, Porcine) 171
GUNA®-HANDFOOT
Osteoarthritis of digits pain
Rhizoarthrosis of the thumb
(Forestier disease)
Arthrosis pain due to hammer toe
Carpal-tunnel syndrome
De Quervain disease
Metacarpal and Metatarsal pain
Morton disease
Rheumatoid arthritis of hand/foot
Hand/Foot tendon pain due to
prolonged immobilization (tendon pain
related to casts)
172
GUNA®-HANDFOOT • Anti interleukin 1 alpha 4C


• Pain symptomatology reduction by pro-inflammatory activity in the
means of UP-REGULATION of b– P.N.E.I. trigger phase of inflammation
Endorphin receptors Anti-inflammatory
antalgic core core
• Pain modulation by means of uric Gout pain Inflammatory

acid crystals accumulation inhibition pain
(drainage action)
Degenerative •Arnica montana 4X
pain •Caulophillum thalictroides 12X
•Ledum palustre 6X
•Benzoicum acidum 6X
•Viola odorata 6X Pain modulation by means of

acute inflammation
•Mercurius solubilis 8X phenomena – vasal in
particular – inhibition
• Pain modulation by means of •Cimicifuga racemosa 10X (arthrosis type)
degenerative process (arthrosis
type) inhibition 173
GUNA®-HIP
Hip joint osteoarthrosis

Hip joint capsule inflammation
Hip joint rheumatoid arthritis
Hip joint pain of muscle origin
Hip joint pain of nerve origin
(burning hip)
Hip joint pain due to prolonged bed
rest
Knee osteoarthrosis
174
GUNA®-HIP •Argentum metallicum 6X
•Arnica montana 8X
•Colocynthis 8X
•Formicum ac. 8X
• Rhus toxicodendron 10X
Reduction of hip pain

symptoms of rheumatic
• Pain symptomatology reduction by
origin :
means of UP-REGULATION of b–
Endorphin receptors P.N.E.I. Homeopathic • Capsule (Formicum ac.,
antalgic core antalgic core Argentum)
• Tendons and ligaments
(Rhus tox)
Anti-
• Constitutional correction of Constitutional inflammatory • Nerves (Colocynthis)
articular structure pathology core core • Muscles (Arnica)
Anti-degenerative
core

• Calcarea fluorica 6X • Anti interleukin 1 beta 4C

• Biostimulation of cartilagineous matrix • Cartilago suis 4X
pro-inflammatory activity in the
components synthesis (Cartilago) • Argentum metallicum 6X trigger phase of inflammation
• New vessels development stimulation
(Argentum)
175
 Small joints rheumatoid arthritis of hand
and foot
Costo-sternal syndrome (Tietze
syndrome)
 Chronic polyarthritis due to auto-immune
diseases (e.g. Lupus erythematosus
sistemicus)
 Broken bone syndrome due to viral or
protozoic disease
 Joint pain due to cancer disease (chronic
leukemia, monoclonal blood diseases)
176
•Beta-Endorphin 4C
• Reduction of polyarticular pain
symptomatology in acute
inflammation having different
localization
reduction by means of UP-
REGULATION of b–Endorphin
P.N.E.I. receptors
antalgic core
•Salycilicum acidum 2X Acute Anti-

•Aconitum 6X inflammatory inflammatory
pain core •Anti interleukin 1 alpha 4C
•Drosera 8X
•Colchicum autumnale 10X •Anti interleukin 1 beta 4C
•Guaiacum 10X Chronic inflammatory

pain

• Reduction of degenerative activity in the trigger
•Ledum palustre 8X phase of inflammation
articular pain on a chronic-
evolutive basis •Viscum album 10X
177
GUNA®-MUSCLE
Trigger points management: acute,

subacute, chronic
Fibromyalgia syndrome
Referred somatic pain area

management
Dermatomyositis
178
Active ingredients: Arnica montana 4X HPUS,
Colocynthis 4X HPUS 4 parts; Belladonna 6X
HPUS, Lithium benzoicum 8X HPUS, Muscle
tissue, Porcine 4C, Procaine chloride 2X 2 parts;
Colchicum autumnale 6X HPUS, Cuprum
sulphuricum 4X HPUS, Hypericum perforatum 4X
HPUS, Interferon gamma 4C 1 part.
Inactive ingredient: Sterile isotonic sodium

chloride solution.
179
GUNA®-MUSCLE
•Arnica montana 4X
•Interferon  4C
•Belladonna 6X
•Procain chloride 2X
•Muscle tissue, Porcine 4C
Anti-
degenerative Contusive
core pain
Spastic or cramp-
Muscular
like pain
rheumatism
• Colchicum autumnale 6X
Sprain
•Lithium benzoicum 8X pain
•Colocynthis 4X
•Cuprum sulphuricum 4X
•Hypericum 4X
180
GUNA®-NEURAL
 Non-specific brachial pain

 Brachial nerve pain due to cervical entrapment
 Intercostal nerve pain due to thoracic entrapment
 Postherpetic neuritis
 Atypical facial neuritis (Slüder syndrome, Charlin
syndrome)
 Trigeminal neuritis
 Pain of the temporomandibular joint (TMJ)
 Arnold syndrome
Cervical, thoracic, lumbar and sacrolumbar nerve
root pain
181
GUNA®-NEURAL •Kalmia latifolia 2X
•Ferrum phosphoricum 2X
•Colocynthis 4X
• Beta-Endorphin 4C •Paris quadrifolia 6X
•Gnaphalium polycephalum 6X
•Iris versicolor 8X
• Pain symptomatology reduction by
means of UP-REGULATION of b– •Aconitum napellus 8X
P.N.E.I.
Endorphin receptors antalgic
Inflammatory
core
aetiology
• Reduction of different
peripheral nerves
Rheumatoid Vascular
aetiology aetiology
inflammation
• Modulation of paresis and
paralysis phenomena Degenerative
aetiology
•Formica rufa 8X
• Kalmia latifolia 2X
•Neurotrophin 4 4C Reduction of pain and

• Trophic action on roots and nerve paraesthetic phenomena by
endings damaged because of means of hyperemetic action
degenerative or lesionary on nerves
phenomena
182
P.R.M. in
Pain Management
•Case n° 1
Left homolateral
lumbago
P.R.M. in Pain Management
•Case n° 1
Left homolateral lumbago
Therapy:
•GUNA®-LUMBAR 1 ampoule
+
•GUNA®-MUSCLE 1 ampoule
+
•GUNA®-NEURAL 1 ampoule

Left homolateral
lumbago
1
2
7
5
6
4
3

P.R.M. in
Pain Management
•Case n° 2
Trapezius myalgia

•Case n° 2
Trapezius myalgia
Therapy:
•GUNA®-MUSCLE 2 ampoule
+
•GUNA®-NEURAL 1 ampoule

Trapezius myalgia
C1
C1 C1
C2
C2 C2
C3C3
C3
C4C4
C4
6 C5C5
C5 1
C6C6
C6
5 2
C7C7
C7
4 3

P.R.M. in
Pain Management
•Case n° 3
Whiplash

•Case n° 3
Whiplash
Therapy:
1° Treatment: 2° Treatment:
•GUNA®-NECK 1 •GUNA®-MUSCLE 1
ampoule ampoule
+
•GUNA®-NEURAL 1
ampoule

Whiplash
(1° treatment)
C1
C1 C1
C2
C2 C2
C3
C3 C3
3 C4
C4 C4
C5
C5 C5
2 C6
C6 C6
C7
C7 C7

Whiplash
(2° treatment)
C1
C1 C1
C2
C2 C2
C3C3
C3
4 C4C4
C4
1
C5C5
C5
3 C6C6
C6
2
C7C7
C7

P.R.M. in
Pain Management
•Case n° 4
Scapular-humeral peri-
artrhitis + 3 trigger
points
•Case n° 4
Scapular-humeral peri-artrhitis
+ 3 trigger points
Therapy:
1° Treatment: 2° Treatment:
•GUNA®-MUSCLE 1 ampoule•GUNA®-SHOULDER 1 ampoule
+ +
•GUNA®-NEURAL 1 ampoule•GUNA®-POLYARTHRITIS 1
ampoule

Scapular-humeral peri-arthritis + 3
trigger points
(1° treatment)
C1
C1 C1
C2
C2 C2
C3C3
C3
C4C4
C4
C5C5
C5
C6C6
C6 2
C7C7
C7

2
3
on the anterior part
of shoulder
Scapular-humeral peri-arthritis + 3
trigger points
P.R.M. in
Pain Management
•Case n° 5
Ankle sprain

•Case n° 5
Ankle sprain
Therapy:
1) Treatment of ankle: 2) Treatment of knee:
• GUNA®-HANDFOOT 1 •GUNA®-HIP 1 ampoule

ampoule

Ankle sprain
(1° treatment)

Ankle sprain
(1° treatment)
4
5
1
2

1
TRAUMATOLOGY - MUSCULAR LESIONS
EXTERNAL CAUSES = MUSCULAR CONTUSION : acute pain, swelling,

painful tumefaction, (in case)
hematoma
THERAPY
-GUNA®-MUSCLE AMPOULES + GUNA®-NEURAL DROPS:

AMPOULES
10 drops 3 times a day, 15
- GUNA®-MATRIX DROPS minutes before meal
- GUNA®-FLAM DROPS
INTERNAL CAUSES = MUSCLE ELONGATION – MUSCULAR CONTRACTION - STRETCHING
THERAPY
- GUNA®-MUSCLE AMPOULES + GUNA®-NEURAL AMPOULES

- GUNA®-FLAM DROPS
- GUNA®-LYMPHO DROPS
201
2
TRAUMATOLOGY - TENDINITIS 80% in Sport
Medicine
TENDINITIS: edema, heat, tendon stiffness

• tendinitis
• tendosynovitis THERAPY
• tendoperiostitis
• etc.
1) CALCANEAN TENDON: 2) BICIPITAL TENDINITIS:

- GUNA®-HAND/FOOT AMPOULES - GUNA®-SHOULDER AMP. + GUNA®-MUSCLE AMP.
- GUNA®-MATRIX DROPS - GUNA®-FLAM DROPS
- GUNA®-FLAM DROPS - GUNA®-MATRIX DROPS
3) TENDON PAIN FROM CASTS: 4) PUBIC PAIN:

- GUNA®-HANDFOOT AMPOULES - GUNA®-HIP AMPOULES
- GUNA®-MATRIX DROPS - GUNA®-FLAM DROPS
- GUNA®-LYMPHO DROPS - GUNA®-LYMPHO DROPS
- GUNA®-MATRIX DROPS
202
3
TRAUMATOLOGY - FRACTURES
- OSTEOBIOSTM DROPS
THERAPY
- GUNA®-FLAM DROPS
+ GUNA®- ….. AMPOULES according to the anatomic localization
(e.g. fracture of femor neck: GUNA®-HIP, fracture of hand bones: GUNA®-
HANDFOOT)
- DISLOCATIONS
- GUNA®-FLAM DROPS
- OSTEOBIOSTM DROPS THERAPY
- GUNA®-LYMPHO DROPS
- in case of shoulder dislocation: add
GUNA®-SHOULDER AMPOULES
203
4
TRAUMATOLOGY - PERIPHERAL NERVE LESIONS
THERAPY
- GUNA®-NEURAL AMPOULES
COMPRESSION SYNDROMES
- GUNA®-FLAM DROPS
SPRAIN SYNDROMES (BRACHIAL PLEXUS)
POSTOPERATIVE PARESIS
- SYNDROMES DUE TO HYPEREXTENSION-HYPERFLEXION
- GUNA®-NECK AMPOULES
THERAPY
- GUNA®-THORACIC AMPOULES
- GUNA®-LUMBAR AMPOULES
204
205
FIBROMYALGIA
 Fibromyalgia is not a new syndrome but a resurrection of

the old “diagnosis” fibrositis
 Fibromyalgia syndrome is a very common chronic illness

whose pathogenesis is reported to be poorly understood
 Women are more affected than men
 All races are affected
206
FIBROMYALGIA
DIAGNOSIS: the patient has to constantly experience the symptoms
for more than 3-4 months and have at least 10 Trigger Points
into the 18 classical sites + disturbed sleep
Commonly associated conditions: irritable bowel syndrome, migraine,

phychic depression, obstructive sleep apnoea, general fatigue
Several causes have been identified: stress, tension, chill,

connective tissue diseases such as
1) osteoarthritis, nerve compression, endocrine imbalance
(estrogen deficiency, hypothyroidism)
2) traumas, repetitive strain, overuse
3) physical-mental fatigue, anxiety
LAB TESTS AND X-RAY: NEGATIVE FOR SPECIFIC DIAGNOSIS
207
THE 18 POINTS TO TEST
POSITIVE POINT: needs to be

painful to a of 4Kg/cm2
pressure applied by the
examiner’s digit
POSITIVE POINT: needs to be

painful when the applied
thumb pressure is sufficient
to blanch the nail-bed of the
doctor’s thumb when he/she
presses firmly on the part
208
FIBROMYALGIA SYNDROME
LOCAL
THERAPY
GUNA®-MUSCLE + GUNA®-NEURAL
2 ampoules (4 ml) + 1 ampoule (2 ml) =
6 ml
INTO EACH TRIGGER POINT: 0.5 ml
TRIGGER POINTS INJECTED PER SESSION: 10 - 12
NUMBER OF SESSIONS: 8 - 10
209
FIBROMYALGIA SYNDROME
HOME
THERAPY
Example:
GUNA®-FLAM DROPS 15 drops 3 times a day 9am – 3pm – 9pm
GUNA®-MATRIX DROPS 15 drops 3 times a day 9.30am – 3.30pm –

9.30pm
GUNA®-SLEEP DROPS 15 – 20 drops a day 10.30 pm

Duration of the therapy: 2 months
210

Manejo Del Dolor Con Medicamentos Guna (Ampollas y Gotas)

Cargado por

Información del documento

Derechos de autor

Formatos disponibles

Compartir este documento

Compartir o incrustar documentos

Opciones para compartir

¿Le pareció útil este documento?

¿Este contenido es inapropiado?

Copyright:

Formatos disponibles

Manejo Del Dolor Con Medicamentos Guna (Ampollas y Gotas)

Cargado por

Copyright:

Formatos disponibles

COMPLEMENTOS CON MEDICAMENTOS

FELIPE TORRES MD.

El dolor es una sensación subjetiva, polimorfa y

La nocicepción comprende dos

1- La transducción del estímulo nocivo

2- La transmisión de esas señales hacia el

El impulso nociceptivo se modula en cada

DIFERENTES TIPOS DE DOLOR:

-AGUDO: Se acompaña de reacciones

-CRONICO (más de 6 meses): Se

Los dolores son clasificados, de acuerdo con su origen, en:

Cuando la sensación dolorosa se produce a nivel de la piel,

El dolor superficial, que se produce por ejemplo luego de

- El primer dolor superficial tiene un carácter agudo, es

- A este dolor superficial primario le sigue a menudo un

El contrapuesto al dolor somático es el dolor visceral.

Se origina por el estímulo de fibras nerviosas, cuando las

Ejemplos de este tipo de dolor es la neuralgia del trigémino y

Además de su origen el dolor puede diferenciarse de acuerdo

El dolor agudo tiene un tiempo limitado, desapareciendo

El dolor crónico puede presentarse como duradero en el

No todos los dolores tienen su origen en los receptores

La afección psicológica puede presentarse bajo una forma

También se ha podido establece la existencia de puntos

Para cada tipo de sensación se han dibujado mapas para cada

Encadenamiento neuronal responsable de la

Existen una categoría de receptores que no pueden ser

1- Lesión tisular originada por punción, presión, rotura o

2- Inflamación tisular consecuente de las anteriores o

3- Isquemia secundaria a la reducción del débito sanguíneo

A pesar de la diversidad de los estímulos, es posible hablar de

Umbral a estímulos elevado: esto se aplica, sobre todo, a

Pequeña superficie del campo receptor.

Descarga de tipo tónico, poco adaptable, persistente después

Inervación por fibras de pequeño diámetro (A delta y C).

KININAS: Son un grupo de sustancias que también actúan

- BRADIKININA: Se libera en las quemaduras

- PROSTAGANDINAS: La PGEl y PGE2, intervienen de

NIVEL PERIFERICO: Con nutrientes:

-Nutrientes que inhiben las citoquinas, prostaglandinas

-Nutrientes que intervienen en la reparación de los tejidos

-Nutrientes de apoyo antioxidante.

La inflamación periférica es regulada por el S.N.C.

La afinidad del TCR, por los complejos peptídicos

El interferon(IFN) se gama o beta se producen

Se puede sufrir el síndrome de las mucosas

Psiconeuroendocrinoinmunologia : interacción entre

Influye la mente en El cerebro y la

The information presented here is not to be

1. LOW DOSE S.K.A. - PRINCIPLES OF HOMEOPATHY

1. NEW CHEMICALS WITH S.K.A. TECHONOLOGY

1. CYTOKINES: ITS RELEVANCE IN PAIN AND

1. EXPERIMENTAL DATA TO VALIDATE CYTOKINE

1. CLINICAL APPLICATION OF LOW DOSE S.K.A. IN

Homeopathic Science Molecular Biology

The science of PRM integrates state of the art scientific advances

© Dipartimento Scientifico Guna S.p.a.

P CENTRAL NERVOUS SYSTEM

Ader, R., Psychoneuroimmunology, IV edition, vol. 1 e 2, Academic Press, Amsterdam

◦ CORTISOL inhibit the Th1 reaction and in

© Dipartimento Scientifico Guna S.p.a.

COMMUNICATING MOLECULES are

EVERY DISEASE IS THE EXPRESSION,

© Dipartimento Scientifico Guna S.p.a.